-
An Open Label Phase 1 Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 with Pembrolizumab Following Radiation Therapy in the Treatment of Non-Small-Cell Lung Cancer Triple-Negative Breast Cancer or Squamous Cell Carcinoma of the Head and Neck that has Progressed on Checkpoint Inhibitors
The purpose of the study is to evaluate the safety, tolerability, and preliminary antitumor activity of TAK-676 and pembrolizumab following radiation therapy in the treatment ... -
A PHASE Ib STUDY EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE (CHP) IN PATIENTS WITH UNTREATED BCL-2 IMMUNOHISTOCHEMISTRY (IHC) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
The purpose of this study is to test two different dosing schedules of an experimental drug called venetoclax. Venetoclax works by blocking a protein in ... -
An Open-label Multicenter Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer
The purpose of the study is to determine the safety and antitumor activity of amivantamab delivered subcutaneously (SC) or under the skin with and without ... -
A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor Alpha (FolRa) Antibody-Drug Conjugate (ADC) in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
The purpose of the study is to determine the safety and efficacy of STRO-002, which is a antibody drug conjugate (ADC) given intravenously every 3 ... -
A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety and tolerability of intravenous (IV) administered CLN-049. CLN-049 is a novel BITE therapy that target ... -
A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)
The purpose of the study is to determine and evaluate the safety, tolerability, and systemic exposure of intravesical enfortumab vedotin. We want to identify the ... -
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
The purpose of the study is to assess the safety and tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab. XmAb®22841 is a ... -
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability ... -
A Phase I First-In-Human Multicenter Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
The purpose of the study is to determine the safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic ... -
A Phase I Open-Label Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended phase 2 dose for FT596 as monotherapy and in combination with rituximab or obinutuzumab for ...